New Insights into Iron Metabolism and Deficiency

This symposium took place on 23rd May 2016, as part of the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Congress 2016 in Vienna, Austria 

Chairperson: Angel de Francisco1
Co-chairperson: Kai-Uwe Eckardt2
Speakers: Kai-Uwe Eckardt,2 Tomas Ganz,3 Jolanta Małyszko4

1. Faculty of Medicine, Cantabria University, Santander, Spain
2. Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, Erlangen, Germany
3. David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA
4. 2nd Department of Nephrology, Medical University Białystok, Białystok, Poland

Disclosure: Prof Kai-Uwe Eckardt has received funding for the German Chronic Kidney Disease study from the German Ministry of Education and Research, and the Foundation for Preventative Medicine (Stiftung Präventivmedizin des KfH). He has also received funding from Amgen, Ardea, Bayer, Dicerna, FMC, Roche Diagnostics, and Vifor. Prof Tomas Ganz has received research grants from the National Institutes of Health, USA, and funding or other forms of support from Merganser Biotech, Silarus Pharma, Keryx Pharma, Vifor, and Intrinsic LifeSciences. Prof Jolanta Małyszko has received funding or other forms of support from Amgen, FMC, and Vifor Fresenius.
Acknowledgements: Writing assistance was provided by Tabasum Mughal of ApotheCom, UK.
The symposium was sponsored by Vifor Fresenius Medical Care Renal Pharma. Authors received honoraria for preparation and delivery of their presentations. The views and opinions expressed are those of the authors and not necessarily of Vifor Fresenius Medical Care Renal Pharma.
Citation: EMJ Nephrol. 2016;4[1]:36-41.

Meeting Summary

The symposium provided an overview of the prevalence of iron deficiency and the associated disease burden in patients with chronic kidney disease (CKD). Prof Kai-Uwe Eckardt gave an overview of the prevalence of iron deficiency in patients with CKD not undergoing dialysis and addressed the challenge of diagnosing iron deficiency in this patient population based on the definitions currently used. Prof Tomas Ganz then reviewed the pathophysiology of iron metabolism, and explained the complex interplay of hepcidin in making iron available for erythropoiesis. The symposium concluded with a presentation from Prof Jolanta Małyszko who reviewed the methods of determining iron status among patients with CKD and compared data on the benefits and risks of intravenous (IV) and oral iron therapy.

Download (PDF, 102KB)


Comments are closed.